17P deletion and TP53 gene mutation (17P/TP53) testing behaviour and treatment patterns for chronic lymphocytic leukemia (CLL) patients in France, Germany, Italy, Spain and UK (EU5)

被引：1
|
作者：
Canta, F. A. Bermudez [1 ]
Mitrofan, L. [2 ]
Karanis, Y. B. [1 ]
Mistry, H. [1 ]
Anger, C. [1 ]
机构：
[1] IMS Hlth, Global Oncol, London, England
[2] IMS Hlth, Global Oncol, La Defence, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw375.14
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
919P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation
    Mikudina, Boglarka
    Goodall, Melinda
    Adler, Amanda I.
    LANCET ONCOLOGY, 2017, 18 (03): : 289 - 290
  • [22] Pediatric brain tumors:: Loss of heterozygosity at 17p and TP53 gene mutations
    Orellana, C
    Hernandez-Martí, M
    Martínez, F
    Castel, V
    Millán, JM
    Alvarez-Garijo, JA
    Prieto, F
    Badía, L
    CANCER GENETICS AND CYTOGENETICS, 1998, 102 (02) : 93 - 99
  • [23] Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
    Lode, Laurence
    Eveillard, Marion
    Trichet, Valerie
    Soussi, Thierry
    Wuilleme, Soraya
    Richebourg, Steven
    Magrangeas, Florence
    Ifrah, Norbert
    Campion, Loic
    Traulle, Catherine
    Guilhot, Francois
    Caillot, Denis
    Marit, Gerald
    Mathiot, Claire
    Facon, Thierry
    Attal, Michel
    Harousseau, Jean-Luc
    Moreau, Philippe
    Minvielle, Stephane
    Avet-Loiseau, Herve
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (11): : 1973 - 1976
  • [24] Copy Number Aberrations are Significantly Increased in High-Risk, Untreated CLL Patients with Chromosome 17p Deletion and TP53 Mutation
    Stone, A.
    Carter, W.
    Frederick, L.
    Zent, C. S.
    Viswanatha, D. S.
    Schichman, S. A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (06): : 870 - 870
  • [25] Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
    Montserrat, Emili
    Dreger, Peter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 : S74 - S81
  • [26] Loss of Heterozygosity (LOH) of 17p (TP53) is Important in the Characterization of Myeloid Neoplasms with Mutated TP53 (MN-mTP53)
    Harrington, Thomas
    Glen Jr, W. Bailey
    Wolff, Daynna
    Park, David
    LABORATORY INVESTIGATION, 2025, 105 (03)
  • [27] 17p Deletion in CLL: Detailed Analysis of TP53 Mutations, Alternative Mechanisms of p53 Inactivation, Clone Size and Clonal Evolution
    Zenz, Thorsten
    Sarno, Antonio
    Haebe, Sonja
    Denzel, Tina
    Mohr, Julia
    Vollmer, Dominik
    Heuberger, Maria
    Winkler, Dirk
    Kienle, Dirk
    Buehler, Andreas
    Truong, Sim
    Patten, Nancy
    Hallek, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2008, 112 (11) : 291 - 291
  • [28] p53 Immunohistochemistry Predicts 17p13(TP53) Deletion in CLL
    Jiang, A.
    Qi, C.
    Chang, H.
    MODERN PATHOLOGY, 2009, 22 : 269A - 269A
  • [29] p53 Immunohistochemistry Predicts 17p13(TP53) Deletion in CLL
    Jiang, A.
    Qi, C.
    Chang, H.
    LABORATORY INVESTIGATION, 2009, 89 : 269A - 269A
  • [30] 17P DELETIONS AND TP53 MUTATIONS IN PATIENTS WITH MDS/AML AND COMPLEX ABERRANT KARYOTYPE
    Schaab, R.
    Ganster, C.
    Dierks, S.
    Parra, M. Tallo
    Martin, R.
    Germing, U.
    Platzbecker, U.
    Shirneshan, K.
    Lange, F.
    Kroeger, N.
    Doehner, K.
    Glass, B.
    Bacher, U.
    Haase, D.
    HAEMATOLOGICA, 2016, 101 : 68 - 68
12345